CoChat

CD28 Down-Regulation on Circulating CD4 T-Cells Is Associated with Poor Prognoses of Patients with Idiopathic Pulmonary Fibrosis

Open access

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Although the etiology of idiopathic pulmonary fibrosis (IPF) remains perplexing, adaptive immune activation is evident among many afflicted patients. Repeated cycles of antigen-induced proliferation cause T-cells to lose surface expression of CD28, and we hypothesized this process might also occur in IPF. METHODOLOGY/PRINCIPAL FINDINGS: Peripheral blood CD4 T-cells from 89 IPF patients were analyzed by flow cytometry and cytokine multiplex assays, and correlated with clinical events. In comparison to autologous CD4(+)CD28(+)cells, the unusual CD4(+)CD28(null) lymphocytes seen in many IPF patients had discordant expressions of activation markers, more frequently produced cytotoxic mediators perforin (2.4+/-0.8% vs. 60.0+/-7.4%, p<0.0001) and granzyme B (4.5+/-2.8% vs.74.9+/-6.5%, p<0.0001), produced greater amounts of many pro-inflammatory cytokines, and less frequently expressed the regulatory T-cell marker FoxP3 (12.9+/-1.1% vs. 3.3+/-0.6% p<0.0001). Infiltration of CD4(+)CD28(null) T-cells in IPF lungs was confirmed by confocal microscopy. Interval changes of CD28 expression among subjects who had replicate studies were correlated with conterminous changes of their forced vital capacities (r(s) = 0.49, p = 0.012). Most importantly, one-year freedom from major adverse clinical events (either death or lung transplantation) was 56+/-6% among 78 IPF patients with CD4(+)CD28(+)/CD4(total)>or=82%, compared to 9+/-9% among those with more extensive CD28 down-regulation (CD4(+)CD28(+)/CD4(total)<82%) (p = 0.0004). The odds ratio for major adverse events among those with the most extensive CD28 down-regulation was 13.0, with 95% confidence intervals 1.6-111.1. CONCLUSIONS/SIGNIFICANCE: Marked down-regulation of CD28 on circulating CD4 T-cells, a result of repeated antigen-driven proliferations, is associated with poor outcomes in IPF patients. The CD4(+)CD28(null) cells of these patients have potentially enhanced pathogenic characteristics, including increased productions of cytotoxic mediators and pro-inflammatory cytokines. These findings show proliferative T-cell responses to antigen(s) resulting in CD28 down-regulation are associated with progression and manifestations of IPF, and suggest assays of circulating CD4 T-cells may identify patients at greatest risk for clinical deterioration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0008959

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Characteristics of CD4 T-cell subpopulations in IPF patients. A: The proportions of circulating CD4 T-cells that also expressed CD28 (CD28%) were reduced in many IPF patients. The horizontal line denotes the population means. B: In contrast to autologous CD4+CD28+ cells, the CD4+CD28null T-cells of IPF patients more often express major histocompatibility antigen (MHC) Class II (DR), but less frequently express CD25. CD4+CD28null T-cells of IPF patients less frequently produce transcription factor FoxP3 (a putative marker of regulatory T-cells), but much more frequently produce cytotoxic mediators granzyme B (GB) and perforin (Perf). For each measure n = 24, and p values for all intergroup comparisons (CD4+CD28+ vrs. CD4+CD28null cells) are <0.0001.
Figure 1 Characteristics of CD4 T-cell subpopulations in IPF patients. A: The proportions of circulating CD4 T-cells that also expressed CD28 (CD28%) were reduced in many IPF patients. The horizontal line denotes the population means. B: In contrast to autologous CD4+CD28+ cells, the CD4+CD28null T-cells of IPF patients more often express major histocompatibility antigen (MHC) Class II (DR), but less frequently express CD25. CD4+CD28null T-cells of IPF patients less frequently produce transcription factor FoxP3 (a putative marker of regulatory T-cells), but much more frequently produce cytotoxic mediators granzyme B (GB) and perforin (Perf). For each measure n = 24, and p values for all intergroup comparisons (CD4+CD28+ vrs. CD4+CD28null cells) are <0.0001.CC BY · PubMed Central
Figure 2 Cytokine elaborations by autologous CD4 subpopulations of IPF patients. Initial (left) data point in each series represents control unstimulated (basal) condition, while second (right) data point delineates productions of cells after stimulation with plate bound anti-CD3 antibody. These paired specimens (control and stimulated) are also connected by lines. CD4+CD28null cells from IPF patients (open circles with paired specimens connected by dashed lines) tend to elaborate greater amounts of pro-inflammatory and TH1 cytokines (top two rows), whereas CD4+CD28+ cells (open squares with paired specimens connected by solid lines) have an apparent TH2 bias, with the exception of IL-4 production (bottom row) (n = 6 randomly-selected specimens in each measure).
Figure 2 Cytokine elaborations by autologous CD4 subpopulations of IPF patients. Initial (left) data point in each series represents control unstimulated (basal) condition, while second (right) data point delineates productions of cells after stimulation with plate bound anti-CD3 antibody. These paired specimens (control and stimulated) are also connected by lines. CD4+CD28null cells from IPF patients (open circles with paired specimens connected by dashed lines) tend to elaborate greater amounts of pro-inflammatory and TH1 cytokines (top two rows), whereas CD4+CD28+ cells (open squares with paired specimens connected by solid lines) have an apparent TH2 bias, with the exception of IL-4 production (bottom row) (n = 6 randomly-selected specimens in each measure).CC BY · PubMed Central
Figure 3 Segregated autologous CD4+CD28+ and CD4+CD28null cells from peripheral blood of IPF patients (n = 9) had similar proliferations (determined by BrdU incorporation) in 5-day control (unstimulated) cultures, as well as after stimulation with plate-bound anti-CD3 monoclonal antibody.
Figure 3 Segregated autologous CD4+CD28+ and CD4+CD28null cells from peripheral blood of IPF patients (n = 9) had similar proliferations (determined by BrdU incorporation) in 5-day control (unstimulated) cultures, as well as after stimulation with plate-bound anti-CD3 monoclonal antibody.CC BY · PubMed Central
Figure 4 Associations of CD28 expression with pulmonary function. Changes of CD28% with replicate testing (Delta CD28%) were significantly correlated with concomittant interval changes of A.) absolute FVC (Delta FVC) and B.) FVC as a time-dependent rate (Delta FVC/month).
Figure 4 Associations of CD28 expression with pulmonary function. Changes of CD28% with replicate testing (Delta CD28%) were significantly correlated with concomittant interval changes of A.) absolute FVC (Delta FVC) and B.) FVC as a time-dependent rate (Delta FVC/month).CC BY · PubMed Central
Figure 5 Associations of CD28% espression with clinical outcome. A.) Survival curves show cumulative freedom from major adverse events (lung transplantation or death) of IPF patients. Those subjects with the most extreme CD28 down-regulation, with CD28 expressed on <82% of their circulating CD4 T-cells (CD28% Low), had much worse outcomes than the cohort with greater proportions of CD4-Tcells that expressed CD28 (CD28% High). Numbers in parenthesis at the ends of survival curves denote remaining, unafflicted subjects that were censored at 12 months of observation. B.) Survival curves showing that cummulative freedom from major adverse events of IPF patients who have either significant CD28 downregulation (CD28% Low) or diffusing capacities for carbon monoxide, as percentages of predicted normal values (DLCO%p) <38, had worse outcomes than the IPF cohort who were both CD28% High and had more normal DLCO%p.
Figure 5 Associations of CD28% espression with clinical outcome. A.) Survival curves show cumulative freedom from major adverse events (lung transplantation or death) of IPF patients. Those subjects with the most extreme CD28 down-regulation, with CD28 expressed on <82% of their circulating CD4 T-cells (CD28% Low), had much worse outcomes than the cohort with greater proportions of CD4-Tcells that expressed CD28 (CD28% High). Numbers in parenthesis at the ends of survival curves denote remaining, unafflicted subjects that were censored at 12 months of observation. B.) Survival curves showing that cummulative freedom from major adverse events of IPF patients who have either significant CD28 downregulation (CD28% Low) or diffusing capacities for carbon monoxide, as percentages of predicted normal values (DLCO%p) <38, had worse outcomes than the IPF cohort who were both CD28% High and had more normal DLCO%p.CC BY · PubMed Central
Figure 6 Localization of CD4, CD3, and granzyme B expressing cells in IPF lungs. A.) and B.) Cells expressing CD4 (Green) and granzyme B (red), respectively, are widely distributed in IPF lung sections. C.) DAPI (blue) stains DNA within cell nuclei. D.) Co-localizations of CD4 and granzyme B (yellow) among nucleated cells are seen in the merged image. Nearly all the intrapulmonary CD4+ cells co-expressed granzyme B. Images E.), F.) and G.) similarly depict CD4 (green), CD3 (red) and DAPI (blue). H.) Merged image shows most of the CD4+ cells also co-expressed CD3. Similar results were present in both IPF lungs. The majority of CD4+ cells in these IPF lung sections co-expressed both granzyme B and CD3 and are, thus, CD4+CD28null T-cells (see also Figure 1B). All images are 60x.
Figure 6 Localization of CD4, CD3, and granzyme B expressing cells in IPF lungs. A.) and B.) Cells expressing CD4 (Green) and granzyme B (red), respectively, are widely distributed in IPF lung sections. C.) DAPI (blue) stains DNA within cell nuclei. D.) Co-localizations of CD4 and granzyme B (yellow) among nucleated cells are seen in the merged image. Nearly all the intrapulmonary CD4+ cells co-expressed granzyme B. Images E.), F.) and G.) similarly depict CD4 (green), CD3 (red) and DAPI (blue). H.) Merged image shows most of the CD4+ cells also co-expressed CD3. Similar results were present in both IPF lungs. The majority of CD4+ cells in these IPF lung sections co-expressed both granzyme B and CD3 and are, thus, CD4+CD28null T-cells (see also Figure 1B). All images are 60x.CC BY · PubMed Central
Figure 7 Flow cytometry methodology (see also references 20, 52). Aliquots of fresh, live peripheral blood mononuclear cells (PBMNC) were stained with anti-CD4-allophycocyanin (APC), anti-CD28-fluorescein isothiocyanate (FITC), and phycoerythrin (PE)-conjugated antibodies against other cell epitopes. A.) Ten thousand (10,000) or more live cells were selected for further study, based their side scatter (SSC) and forward scatter (FSC) characteristics (G1). B.) The brightly staining CD4 cells among these also expressed CD3 (Cy-Chrome) and, thus, are T-cells [52]. C.) These CD4 T-cells were further characterized based on their expression of CD28. The proportions of CD4+CD28+ T-cells among the total CD4+ T-cell population (upper left and upper right quadrants) defines the CD28%. The respective proportions of CD4+CD28+ and CD4+CD28null cells that co-expressed other cell determinants of interest (in this case MHC Class II [DR]) were quantitated. Numbers within the delineated region/quadrants denote the proportions of cells with these respective characteristics.
Figure 7 Flow cytometry methodology (see also references 20, 52). Aliquots of fresh, live peripheral blood mononuclear cells (PBMNC) were stained with anti-CD4-allophycocyanin (APC), anti-CD28-fluorescein isothiocyanate (FITC), and phycoerythrin (PE)-conjugated antibodies against other cell epitopes. A.) Ten thousand (10,000) or more live cells were selected for further study, based their side scatter (SSC) and forward scatter (FSC) characteristics (G1). B.) The brightly staining CD4 cells among these also expressed CD3 (Cy-Chrome) and, thus, are T-cells [52]. C.) These CD4 T-cells were further characterized based on their expression of CD28. The proportions of CD4+CD28+ T-cells among the total CD4+ T-cell population (upper left and upper right quadrants) defines the CD28%. The respective proportions of CD4+CD28+ and CD4+CD28null cells that co-expressed other cell determinants of interest (in this case MHC Class II [DR]) were quantitated. Numbers within the delineated region/quadrants denote the proportions of cells with these respective characteristics.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 209

Metadata

Authors
Gilani, S. R., Vuga, L. J., Lindell, K. O., Gibson, K. F., Xue, J., Kaminski, N., Valentine, V. G., Lindsay, E. K., George, M. P., Steele, C., & Duncan, S. R.
Affiliations
  • University of Pittsburgh (US)
  • The University of Texas Medical Branch at Galveston (US)
  • University of Alabama at Birmingham (US)
Corresponding author
Duncan, Steven R.
Venue
PLoS ONE
Published
2010-01-29
Volume
5
Issue
1
Pages
e8959
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1976574577
Cited by
203
References
54
Citations by year
2026: 5 · 2025: 7 · 2024: 15 · 2023: 14 · 2022: 11 · 2021: 12 · 2020: 9 · 2019: 9 · 2018: 18 · 2017: 14 · 2016: 11 · 2015: 14 · 2014: 13 · 2013: 18 · 2012: 18
FWCI
13.56
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • University of Pittsburgh
  • National Institutes of Health (5r01hl073241-04, 5p50hl084932-05)
  • National Heart, Lung, and Blood Institute (R01 HL073241, P50-HL-084932, 1P50 HL084932, 1R01HL073241, T32HL007563)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
idiopathic pulmonary fibrosis, CD4+ T cells, T cell exhaustion, prognostic factors, perforin, granzyme B, Foxp3+ regulatory T cells, inflammatory cytokines, lung transplantation, forced vital capacity, adaptive immune activation, lung infiltration, major adverse clinical events, T cell activation markers
MeSH terms
Adult, Humans, Male, Prognosis, Pulmonary Fibrosis, CD4-Positive T-Lymphocytes, Down-Regulation, CD28 Antigens

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD28 Down-Regulation on Circulating CD4 T-Cells Is Associated with Poor Prognoses of Patients with Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1371/journal.pone.0008959
The paper
Gilani, S. R., Vuga, L. J., Lindell, K. O., Gibson, K. F., Xue, J., Kaminski, N., Valentine, V. G., Lindsay, E. K., George, M. P., Steele, C., & Duncan, S. R. (2010). CD28 Down-Regulation on Circulating CD4 T-Cells Is Associated with Poor Prognoses of Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE. https://doi.org/10.1371/journal.pone.0008959

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.